Search Results for: MET

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
STAT3 signal transducer and activator of transcription 3
  • Interleukin-6 signaling
  • BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Downstream signal transduction
  • Signalling to STAT3
  • Senescence-Associated Secretory Phenotype (SASP)
  • Signaling by Leptin
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Association of TriC/CCT with target proteins during biosynthesis
  • Transcriptional regulation of pluripotent stem cells
  • Interleukin-10 signaling
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Activates STAT3
  • PTK6 Activates STAT3
  • Interleukin-20 family signaling
  • MET activates STAT3
  • MET activates STAT3
  • Interleukin-15 signaling
  • Interleukin-35 Signalling
  • Interleukin-9 signaling
  • Interleukin-37 signaling
  • Interleukin-23 signaling
  • Interleukin-23 signaling
  • Interleukin-27 signaling
  • Interleukin-21 signaling
  • Transcriptional regulation of granulopoiesis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Growth hormone receptor signaling
  • ENMD-1198
  • Other well-defined immunodeficiency syndromes, including the following seven diseases: Wiskott-Aldrich syndrome; DiGeorge syndrome; Hyper-IgE syndrome; X-linked lymphoproliferative syndrome; Immunodeficiency, Polyendocrinopathy, Enteropathy, X-linked Syndrome (IPEX); Cartilage-Hair Hypoplasia; Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED)
  • Oral cancer
ERBB2 erb-b2 receptor tyrosine kinase 2
  • Signaling by ERBB2
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Sema4D induced cell migration and growth-cone collapse
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Constitutive Signaling by Overexpressed ERBB2
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Trastuzumab
  • Lapatinib
  • IGN311
  • Trastuzumab emtansine
  • Varlitinib
  • AV-412
  • Pertuzumab
  • Afatinib
  • Tucatinib
  • Tesevatinib
  • Fostamatinib
  • Brigatinib
  • Margetuximab
  • Zanubrutinib
  • Choriocarcinoma
  • Pancreatic cancer
  • Gastric cancer
  • Bladder cancer
  • Endometrial Cancer
  • Ovarian cancer
  • Cholangiocarcinoma
  • Breast cancer
  • Cervical cancer
SHC1 SHC adaptor protein 1
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signalling to RAS
  • SHC1 events in EGFR signaling
  • Tie2 Signaling
  • Integrin signaling
  • XBP1(S) activates chaperone genes
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Constitutive Signaling by EGFRvIII
  • RAF/MAP kinase cascade
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Insulin receptor signalling cascade
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • Interleukin-2 signaling
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Interleukin receptor SHC signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
CTNNB1 catenin beta 1
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • TCF dependent signaling in response to WNT
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • Apoptotic cleavage of cell adhesion proteins
  • Deactivation of the beta-catenin transactivating complex
  • Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
  • Ca2+ pathway
  • Adherens junctions interactions
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Myogenesis
  • Myogenesis
  • Signaling by GSK3beta mutants
  • S33 mutants of beta-catenin aren't phosphorylated
  • S37 mutants of beta-catenin aren't phosphorylated
  • S45 mutants of beta-catenin aren't phosphorylated
  • T41 mutants of beta-catenin aren't phosphorylated
  • RHO GTPases activate IQGAPs
  • Transcriptional Regulation by VENTX
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX3 regulates WNT signaling
  • Urea
  • Gastric cancer
  • Colorectal cancer
  • Endometrial Cancer
  • Pilomatricoma; Epithelioma calcificans of Malherbe
  • Thyroid cancer
  • Hepatocellular carcinoma
GAB1 GRB2 associated binding protein 1
  • PI3K Cascade
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • PI3K events in ERBB2 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Constitutive Signaling by EGFRvIII
  • PI-3K cascade:FGFR1
  • PI-3K cascade:FGFR2
  • PI-3K cascade:FGFR3
  • PI-3K cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PI3K/AKT signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • MET activates PTPN11
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Activated NTRK2 signals through PI3K
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
SYK spleen associated tyrosine kinase
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • FCGR activation
  • FCGR activation
  • Regulation of actin dynamics for phagocytic cup formation
  • Role of phospholipids in phagocytosis
  • DAP12 signaling
  • Fc epsilon receptor (FCERI) signaling
  • Fc epsilon receptor (FCERI) signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Integrin signaling
  • CLEC7A (Dectin-1) signaling
  • Dectin-2 family
  • Dectin-2 family
  • Interleukin-2 signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Staurosporine
  • N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide
  • Tamatinib
  • 2-{2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl}-N-[(1S)-2-hydroxy-1-methylethyl]-4-methyl-1,3-thiazole-5-carboxamide
  • 2-{[(1R,2S)-2-aminocyclohexyl]amino}-4-[(3-methylphenyl)amino]pyrimidine-5-carboxamide
  • Ellagic acid
  • Fostamatinib
VAV1 vav guanine nucleotide exchange factor 1
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • CD28 dependent Vav1 pathway
  • G alpha (12/13) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • VEGFR2 mediated vascular permeability
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
LCK LCK proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Nef Mediated CD4 Down-regulation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • PD-1 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Interleukin-2 signaling
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • FLT3 signaling through SRC family kinases
  • Dasatinib
  • AP-22408
  • Staurosporine
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
  • 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
  • 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
  • N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
  • N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
  • Ponatinib
  • Nintedanib
  • Fostamatinib
  • Zanubrutinib
  • Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
ITGB1 integrin subunit beta 1
  • Elastic fibre formation
  • Fibronectin matrix formation
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Cell surface interactions at the vascular wall
  • Basigin interactions
  • Molecules associated with elastic fibres
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Laminin interactions
  • Laminin interactions
  • Syndecan interactions
  • ECM proteoglycans
  • Other semaphorin interactions
  • Signal transduction by L1
  • Localization of the PINCH-ILK-PARVIN complex to focal adhesions
  • CHL1 interactions
  • RHO GTPases Activate Formins
  • Interleukin-4 and Interleukin-13 signaling
  • Platelet Adhesion to exposed collagen
  • MET activates PTK2 signaling
  • MET interacts with TNS proteins
  • HCMV Early Events
  • Potential therapeutics for SARS
  • Antithymocyte immunoglobulin (rabbit)
  • MK-0668
CBL Cbl proto-oncogene
  • Interleukin-6 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Spry regulation of FGF signaling
  • Regulation of KIT signaling
  • EGFR downregulation
  • TGF-beta receptor signaling activates SMADs
  • Constitutive Signaling by EGFRvIII
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Negative regulation of MET activity
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Negative regulation of FLT3
  • FLT3 signaling by CBL mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
YES1 YES proto-oncogene 1, Src family tyrosine kinase
  • Signaling by ERBB2
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • FCGR activation
  • PECAM1 interactions
  • EPH-Ephrin signaling
  • CD28 co-stimulation
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • EPH-ephrin mediated repulsion of cells
  • RUNX2 regulates osteoblast differentiation
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Dasatinib
  • Fostamatinib
CDK4 cyclin dependent kinase 4
  • SCF(Skp2)-mediated degradation of p27/p21
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • RMTs methylate histone arginines
  • Transcriptional regulation of white adipocyte differentiation
  • Cyclin D associated events in G1
  • Ubiquitin-dependent degradation of Cyclin D
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates Cell Cycle
  • Transcriptional regulation by RUNX2
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4
  • Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Purvalanol
  • Alvocidib
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Fostamatinib
  • Glioma
  • Malignant melanoma
  • Cervical cancer
PIK3R3 phosphoinositide-3-kinase regulatory subunit 3
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Interleukin-7 signaling
  • Signaling by SCF-KIT
  • Synthesis of PIPs at the plasma membrane
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Costimulation by the CD28 family
  • CD28 dependent PI3K/Akt signaling
  • G alpha (q) signalling events
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • RET signaling
  • Extra-nuclear estrogen signaling
  • Interleukin receptor SHC signaling
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Isoprenaline
  • SF1126
HGF hepatocyte growth factor
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • Heparin
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • ABT-510
  • Foretinib
PLCG2 phospholipase C gamma 2
  • GPVI-mediated activation cascade
  • Toll Like Receptor 4 (TLR4) Cascade
  • Synthesis of IP3 and IP4 in the cytosol
  • Generation of second messenger molecules
  • Role of phospholipids in phagocytosis
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • CLEC7A (Dectin-1) signaling
  • CLEC7A (Dectin-1) signaling
  • Dectin-2 family
  • Dectin-2 family
  • Erythropoietin activates Phospholipase C gamma (PLCG)
  • FCGR3A-mediated IL10 synthesis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
VAV2 vav guanine nucleotide exchange factor 2
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • EPH-ephrin mediated repulsion of cells
  • G alpha (12/13) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • VEGFR2 mediated vascular permeability
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
VAV3 vav guanine nucleotide exchange factor 3
  • GPVI-mediated activation cascade
  • GPVI-mediated activation cascade
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • EPH-ephrin mediated repulsion of cells
  • G alpha (12/13) signalling events
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
BTK Bruton tyrosine kinase
  • ER-Phagosome pathway
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • Regulation of actin dynamics for phagocytic cup formation
  • DAP12 signaling
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • G alpha (q) signalling events
  • G alpha (12/13) signalling events
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • RHO GTPases Activate WASPs and WAVEs
  • G beta:gamma signalling through BTK
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • Inositol 1,3,4,5-Tetrakisphosphate
  • XL418
  • Ibrutinib
  • Acalabrutinib
  • Fostamatinib
  • Zanubrutinib
  • Abivertinib
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
  • Pituitary Dwarfism (PD); Isolated growth hormone deficiency (IGHD); Short Stature and Pituitary Defects (SSPD); Insulin-like growth factor 1 deficiency (IGFD)
CASP3 caspase 3
  • Activation of caspases through apoptosome-mediated cleavage
  • SMAC (DIABLO) binds to IAPs
  • SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes
  • Apoptotic cleavage of cellular proteins
  • SMAC, XIAP-regulated apoptotic response
  • Apoptosis induced DNA fragmentation
  • Degradation of the extracellular matrix
  • Signaling by Hippo
  • NADE modulates death signalling
  • Stimulation of the cell death response by PAK-2p34
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Apoptotic cleavage of cell adhesion proteins
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Other interleukin signaling
  • Pamidronic acid
  • Acetylsalicylic acid
  • Minocycline
  • 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
  • Emricasan
  • Incadronic acid
  • 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
  • methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
  • 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
  • [N-(3-dibenzylcarbamoyl-oxiranecarbonyl)-hydrazino]-acetic acid
  • 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
  • (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • N-[3-(2-fluoroethoxy)phenyl]-N'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
  • Glycyrrhizic acid
MYC MYC proto-oncogene, bHLH transcription factor
  • Transcription of E2F targets under negative control by DREAM complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Binding of TCF/LEF:CTNNB1 to target gene promoters
  • MAPK6/MAPK4 signaling
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • Cyclin E associated events during G1/S transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • TFAP2 (AP-2) family regulates transcription of cell cycle factors
  • RUNX3 regulates WNT signaling
  • Estrogen-dependent gene expression
  • Transcriptional regulation of granulopoiesis
  • Acetylsalicylic acid
  • Nadroparin
  • Choriocarcinoma
  • Penile cancer
  • Burkitt lymphoma
  • Oral cancer
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
  • Multiple myeloma
  • Small cell lung cancer
  • Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
  • Osteosarcoma
  • Kaposi's sarcoma
  • Laryngeal cancer
  • Breast cancer
  • Ovarian cancer

Page 2 out of 7 pages